Holen Sie sich die Stockscreener-App
1.68
3.70%
0.06
Handel nachbörslich:
1.65
-0.03
-1.79%
Schlusskurs vom Vortag:
$1.62
Offen:
$1.645
24-Stunden-Volumen:
137.67K
Relative Volume:
0.15
Marktkapitalisierung:
$181.91M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-3.2308
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
+6.33%
1M Leistung:
+20.86%
6M Leistung:
-34.12%
1J Leistung:
+20.00%
1-Tages-Spanne:
$1.64
$1.68
1-Wochen-Bereich:
$1.56
$1.78
52-Wochen-Spanne:
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Vergleichen Sie ACRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.68 | 175.42M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-05-28 | Eingeleitet | Wedbush | Outperform |
| 2025-03-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-11-19 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Eingeleitet | Evercore ISI | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-10-06 | Eingeleitet | BTIG Research | Buy |
| 2021-07-23 | Fortgesetzt | Jefferies | Buy |
| 2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-09 | Eingeleitet | Guggenheim | Buy |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
| 2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-06-10 | Eingeleitet | Guggenheim | Buy |
| 2015-11-02 | Eingeleitet | Citigroup | Buy |
| 2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
LENZ Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital appreciation - Autocar Professional
Aclaris Therapeutics Inc. Stock Analysis and ForecastTremendous financial leverage - jammulinksnews.com
What drives Aclaris Therapeutics Inc. stock priceDynamic growth stocks - jammulinksnews.com
Is Aclaris Therapeutics Inc. a good long term investmentRapid capital growth - jammulinksnews.com
How Aclaris Therapeutics Inc. stock performs during market volatilityStrong Return Daily Alerts - Newser
What analysts say about Aclaris Therapeutics Inc. stockPhenomenal trading returns - jammulinksnews.com
Why Aclaris Therapeutics Inc. stock attracts strong analyst attentionGroup Only Stock Signals - Newser
What makes Aclaris Therapeutics Inc. stock price move sharplyEntry Level Low Risk Picks - Newser
Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases - Insider Monkey
13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey
Piper Sandler Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.50m - simplywall.st
Plus Therapeutics (NASDAQ:PSTV) vs. Aclaris Therapeutics (NASDAQ:ACRS) Head-To-Head Survey - Defense World
Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Aclaris Therapeutics at HCW Conference: Strategic Moves and Future Plans By Investing.com - Investing.com Canada
Aclaris Therapeutics joins Russell 3000 and Russell 2000 indexes - Investing.com
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Aclaris Added to Russell Indexes: $10.6T in Benchmark Assets Now Track Biotech Stock - Stock Titan
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Completeness Index - MarketScreener
Aclaris Therapeutics joins Russell 3000 and Russell 2000 indexes By Investing.com - Investing.com UK
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference - The Manila Times
Aclaris Therapeutics to Present at H.C. Wainwright Inflammation & Immunology Virtual Conference on June 30, 2025 - Nasdaq
Aclaris Therapeutics (NASDAQ:ACRS) Receives “Buy” Rating from HC Wainwright - Defense World
Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 - MSN
Aclaris Therapeutics (NASDAQ:ACRS) Given Outperform Rating at Wedbush - Defense World
Assenagon Asset Management S.A. Purchases 284,191 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $9.71 Consensus Price Target from Analysts - Defense World
Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 26% - simplywall.st
Aclaris at Goldman Sachs Conference: Strategic Focus on Immuno-inflammatory Pipeline By Investing.com - Investing.com South Africa
Aclaris at Goldman Sachs Conference: Strategic Focus on Immuno-inflammatory Pipeline - Investing.com Australia
Bank of America Corp DE Buys 196,708 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.91%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):